Mineralys Therapeutics (NASDAQ: MLYS) — Perfil da empresa, notícias e dados financeiros
Mineralys Therapeutics develops innovative treatments for hypertension, focused on improving patient outcomes in cardiovascular health.
Mineralys Therapeutics
Mineralys Therapeutics (NASDAQ: MLYS) focuses on developing innovative treatments designed to address significant unmet medical needs in the cardiovascular space, specifically targeting hypertension and related disorders. Dedicated to pushing the boundaries of medical science, Mineralys aims to create therapies that can significantly improve patient outcomes and overall quality of life. The company is committed to advancing its research and development efforts, with a keen emphasis on novel drug candidates that promise a safer, more effective approach to managing high blood pressure and its complications. Through these endeavors, Mineralys is steadfast in its objective to revolutionize the treatment landscape for patients worldwide, striving to bring groundbreaking solutions from the lab bench to the bedside.
Resumo
Operações
Produtos e/ou serviços de Mineralys Therapeutics
- Development of a novel hypertension treatment aimed at addressing the underlying causes by targeting aldosterone.
- Research into treatments for chronic kidney disease linked with hypertension.
- Innovative therapy solutions for cardiovascular diseases related to aldosterone dysregulation.
- Exploration of potential medications for heart failure patients with a focus on aldosterone inhibitors.
- Advanced diagnostic tools for the early detection of aldosterone-related disorders.
- Collaboration on clinical trials for new drug delivery systems aimed at improving patient compliance and outcomes.
equipe executiva do Mineralys Therapeutics
- Jon CongletonPresident, CEO & Director
- Brian Taylor SlingsbyFounder & Executive Director
- Adam Scott LevyCFO & Secretary
- Jeffrey A. MunsieChief Legal Officer
- Robert McKeanSenior Vice President of CMC
- Danielle MahoneySenior Vice President of Quality Assurance
- Jessica IbbitsonExecutive Vice President of Operations
- Eric J. WarrenChief Commercial Officer
- Michael TortoriciSenior Vice President of Translational Medicine
- James J. Ferguson IIIChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Mineralys Therapeutics , em USD.
- Cap. de mercado
- 1,9 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -4.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -170,6 mi | -154,7 mi | |
| 0 | -192,4 mi | -177,8 mi | |
| 0 | -84,7 mi | -71,9 mi | |
| 0 | -31,5 mi | -29,8 mi |